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Abstract
The leading cause of dementia is Alzheimer’s disease (AD), which affects millions worldwide. Aging populations 
can foretell the worsening burden of the disease in the future. AD is characterised by the following hallmark 
pathologies: amyloid-β over-production and deposition, abnormal hyperphosphorylation of tau leading to the 
formation of neurofibrillary tangles, and neuroinflammation. Many potential treatments fail in clinical trials, 
suggesting that present theories are outdated or lead to therapeutic dead-ends. A gum disease-causing species 
of bacteria, Porphyromonas gingivalis, is being increasingly linked with AD, given the ubiquity of gum disease 
amongst older populations, and studies have revealed that the bacteria causes and exacerbates AD pathology 
both in vitro and in vivo. P. gingivalis produce many neurotoxic molecules, including gingipain enzymes, lipopoly-
saccharide and phosphoglycerol dihydroceramides, and all of these have been shown to affect AD pathologies. 
Numerous mechanisms by which these neurotoxic species reach the brain have been proposed, and one of these 
is the bacteria’s use of outer membrane vesicles. This review presents the present evidence of the effects of P. gin-
givalis and its outer membrane vesicles, gingipains, lipopolysaccharide and phosphoglycerol dihydroceramides, 
on neurodegeneration in neuronal cultures, mice models and post-mortem studies, and determines how this 
evidence can be used to develop new treatments for AD.
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Introduction
Alzheimer’s Disease (AD) is a neurodegenerative disease, and 
the main cause of dementia, causing 60–70% of cases worldwide. 
Globally, there are approximately 50 million people with demen-
tia.1 At present, there are no treatment options for chronic AD.2 
Tanzi (2012) asserted that the two biggest risk factors for the de-
velopment of AD are age and genetics,3 although environmental 
factors, immune system dysfunction and infections are all closely 
linked to AD.4 The two key AD pathologies are the presence of 
extracellular amyloid-β (Aβ) plaques and neurofibrillary tangles 
(NFTs) that form from abnormally hyperphosphorylated tau.5
The amyloid cascade hypothesis suggests that Aβ protein causes 
AD.6 Aβ is produced from amyloid precursor protein (APP) using 
enzymes β-secretase and γ-secretase in the amyloidogenic path-
way of APP processing.5 Chen et al. (2017) stated that Aβ mono-
mers form extracellular plaques,6 However, the relationship of Aβ 
plaques to cognitive impairment and neurodegeneration remains 
unclear, since there is no strong correlation between these.7 Nev-
ertheless, small aggregations of Aβ, called oligomers, appear to be 
the most neurotoxic form of Aβ. These can easily spread through-
out the brain, and cause mitochondrial dysfunction and oxidative 
stress in neurons, contributing to neuronal death (Fig. 1).6,8 The 
tau protein is a microtubule-associated protein (MAP), and a key 
part of a neuron’s cytoskeleton.9 The phosphorylation of tau con-
trols the function of tau, and is balanced by kinase and phosphatase 
activity.10 The enzymes involved in tau phosphorylation involve 
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a number of kinases, such as GSK3β, PKA, PKB, and various 
phosphatases. The main phosphatase of tau is protein phosphatase 
2A (PP2A), although PP1, PP3 and PP5 can also act on tau.10 In 
AD, both kinases and phosphatases become dysregulated, such 
that tau is abnormally hyperphosphorylated.10 These reduce the 
normal function of tau and forms abnormally hyperphosphoryl-
ated tau (AD P-tau).9 AD P-tau self-assembles into NFTs.9 NFTs 
cause neurofibrillary degeneration, which involves the impairment 
of function of normal tau, causing cytoskeletal breakdown,11 and 
the impairment of Golgi bodies and mitochondria,11,12 and disrupt-
ing synapses,2 leading to the death of affected neurons, and sub-
sequently, neurodegeneration (Fig. 1).11 Glycogen synthase kinase 
3β (GSK3β) is a widely expressed kinase in the central nervous 
system (CNS), which is overactive in AD, and plays a large role in 
the hyperphosphorylation of tau and the modulation of APP amy-
loidogenic processing, leading to Aβ formation.13,14 Hippocampal 
GSK3β expression is high. This has been considered to play a vital 
role in hippocampal long-term potentiation (LTP), long-term de-
pression (LTD) and neurogenesis, and all of which are key pro-
cesses in memory formation/consolidation. In addition, it has been 
shown that GSK3β inhibition can promote the proliferation, mi-
gration and differentiation of neural stem cells.14 When overactive, 
as observed in AD, GSK3β activation can impair LTP and promote 
LTD.14 The production of pro-inflammatory cytokine, tumour 
necrosis factor-alpha (TNF-α), is dependent on GSK3β to some 
extent,13 and contributes to neuroinflammation, alongside other 
cytokines, such as IL-1α/β and IL-6.15 Microglia, which are im-
mune cells of the brain, are responsible for much of the production 
of pro-inflammatory cytokines in the CNS, and often responds to 
pathogens/pathogenic insults, resulting in neuroinflammation.15,16 
The lack of hippocampal neurogenesis caused by aberrant GSK3β 
activity can also activate the pro-inflammatory state of microglia.14 
Microglia can adopt a number of different phenotypes that alter the 
cytokines they produce,17 despite being once considered to able to 
adopt one of the two microglial phenotypes: M1 (pro-inflammato-
ry state) or M2 (anti-inflammatory state).17 However, this theory 
is becoming outdated, and a number of studies have suggested that 
there are more than two microglial phenotypes.17 Neuroinflamma-
tion is highly common in AD patients,15,18 and is strongly impli-
cated in neurodegeneration in many ways. One example of how 
this occurs is the microglial production of pro-inflammatory cy-
tokines.15,17,18 The cytokines produced by microglia contribute to 
neuroinflammation in numerous ways, and have numerous effects. 
One of these is to induce astrocytes to adopt to their A1 phenotype. 
A1 astrocytes lose their regular homeostatic functions, such as the 
formation of synapses (synaptogenesis), and instead induce apop-
tosis in neurons and glia, causing neurodegeneration (Fig. 1).15,18
There is an urgent need to find effective treatments for AD. A 
number of present therapies treat psychotic symptoms/depression 
without affecting the causes.2 AD treatments include β-secretase 
inhibition and the upregulation of phosphatases to lower tau phos-
phorylation,2 but most of these are ineffective or even toxic.19 
Huang et al. (2020) listed nine different treatments for AD that 
failed in phase 3 trials between 2016 and 2019 alone.20
Porphyromonas gingivalis is a gram-negative gum-disease 
(periodontitis) causing bacteria linked to AD,21 and there are mul-
tiple ways by which P. gingivalis has been shown to influence AD 
pathologies. The bacterial key neurotoxic secretions are gingipain 
enzymes, lipopolysaccharide (LPS) and phosphoglycerol dihy-
droceramide (PGDHC), which can be released in outer membrane 
Fig. 1. Outline of amyloid-β and tau’s contributions to dementia. The amyloid precursor protein (APP) is converted to amyloid-β, which allows amyloid-β 
plaques and oligomers to form, causing neurodegeneration. Tau forms abnormally hyperphosphorylated tau (AD P-tau) that aggregates into neurofibrillary 
tangles, which cause neurofibrillary degeneration. Alzheimer’s disease is a complicated disease, in which a number of key factors play a role. The figure 
presents a basic overview of the fundamentals. Porphyromonas gingivalis can influence the formation of amyloid-β and AD P-tau, and neuroinflamma-
tion, causing/exacerbating the AD pathology. AD, Alzheimer’s disease; AD P-tau, abnormally-hyperphosphorylated tau; APP, amyloid precursor protein; Aβ, 
amyloid-β protein; BBB, blood-brain barrier; GSK3β, glycogen synthase kinase 3β; IL-1β, interleukin-1β; NFTs, neurofibrillary tangles.
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vesicles (OMVs) in the body, and reach distant areas from the orig-
inal site of infection in the oral cavity through blood, such as the 
brain.22–24 The bacteria, their OMVs and their virulence factors are 
able to enter the brain following infection of the oral cavity, and 
influence AD.22,23 These have been confirmed by their presence in 
post-mortem AD brains, but not in non-AD brains.24,25 Aβ is an an-
timicrobial peptide that causes neuroinflammation.26 Implying Aβ 
deposition can initially be a response to infection in the brain. P. 
gingivalis are iron auxotrophs,22,27 which is significant, given that 
cortical iron dysregulation and subsequent deposition are correlated 
with and theorised to accelerate Aβ deposition, tau aggregation and 
neurodegeneration.28 Iron is toxic to neurons via the generation of 
reactive oxygen species (ROS).22,27 In AD brains, iron depositions 
are often co-localised with Aβ accumulation, NFTs and gingipain 
accumulation,22,27 and these areas present with neurodegeneration, 
oxidative stress and mitochondrial dysfunction.22,28 P. gingivalis, 
which breaks down salivary lactoferrin in the oral cavity to receive 
the iron it needs, may seek for the AD brain when salivary lactofer-
rin levels are reduced. This is attributable to hypothalamic lesions 
(which dysregulates salivary secretions as a result), causing oral 
dysbiosis.22,27 Although the levels are lowered in the saliva, lacto-
ferrin is upregulated in AD brains, and has neuroprotective effects 
against iron, Aβ deposition and NFT formation, as well as against 
oxidative stress and mitochondrial dysfunction.22 P. gingivalis is 
a powerful lactoferrin degrader, and this likely acts to reduce the 
neuroprotective effects that lactoferrin have in AD brains.22
There are several other pathogens linked to AD (Table 1),21,29 
although P. gingivalis is of special interest and given the preva-
lence of gum disease. Nearly 50% of the adult population were 
observed to have some form of periodontitis in a US study,30 while 
another study revealed that 61.9% of participants had periodon-
titis, with age being the most significant risk factor.31 Given that 
periodontitis is treatable, this offers potential targets for AD thera-
pies.29 The present review aims to discuss the role of P. gingivalis 
in neurodegeneration and AD, and determine how targeting this 
can lead to new AD treatments.
Porphyromonas gingivalis, periodontitis and AD
A growing body of evidence has shown that P. gingivalis is able 
to increase Aβ production, tau phosphorylation and neuroinflam-
mation, contributing to AD (Fig. 2).32–35 P. gingivalis causes peri-
odontitis, elevates pro-inflammatory cytokine levels, and causes 
inflammation.36 Furthermore, cytokines can increase blood-brain 
barrier (BBB) permeability, which can allow P. gingivalis, OMVs, 
or its secretions to cross.21 The post-mortems of AD brains re-
vealed the bacteria and virulence factors in both the brain and 
cerebrospinal fluid.25 Noble et al. (2009) reported the correlation 
between increasing P. gingivalis antibody levels and cognitive im-
pairment, suggesting that P. gingivalis causes cognitive decline,37 
although the study used secondary data in excess of 15 years old. 
Furthermore, the findings were solely correlational, but were sig-
nificant nevertheless.
P. gingivalis induces AD pathology. The bacteria and/or its se-
cretions invade the brain, significantly increasing Aβ deposits in 
the brain, and raising pro-inflammatory cytokine levels.21 Further-
more, P. gingivalis activates microglia, degenerates neurons, and 
increases tau hyperphosphorylation and the subsequent formation 
of NFTs, leading to neurofibrillary degeneration.23 Moreover, P. 
gingivalis has been shown to increase tau phosphorylation in wild-
type mice models by inducing the neuroinflammation-mediated 
production of IL-1β that inhibits PP2A.35 In studies that have 
shown this result, the effects developed within a reasonably short 
period of time, in only 22 weeks after initial infection in one study, 
and even in young adult wild-type mice.23 This clearly demon-
strates the link of P. gingivalis to AD, and the ability to accelerate 
AD pathogenesis.
Interestingly, P. gingivalis and its secretions are adept in evad-
ing and attenuating immune response in a wider body, as well as 
in the brain, with the latter’s response being mediated by micro-
glia and the complement system.38,39 This allows for the persistent 
presence of bacteria and its secretions in the brain, exacerbating the 
effects these have on AD pathology over a longer period of time. 
Gingipains inhibit the complement system by breaking down the 
C3 protein, which is central to complement system activation, and 
gingipains can also degrade toll-like receptor (TLR) coreceptors, 
cytokines and antimicrobial peptides.38 LPS resists complement-
mediated lysis and upregulates negative regulator TLRs in mono-
cytes/microglia.38 This information is significant when consider-
ing the importance of an effective immune response to eliminate 
P. gingivalis and its virulence factors from the brain. The nuances 
of the expertise of P. gingivalis in evading immune response38,39 
must be considered when therapeutically targeting the bacteria and 
secretions.
In order to best understand the bacteria’s role in AD, it is nec-
essary to first discuss the effects of each key secretions on the 
neurons/brain, and the contributions to neurodegeneration and AD 
(Fig. 2).
Table 1.  Other pathogens associated with Alzheimer’s disease21
Pathogens
Viruses Bacteria Fungal Protozoa
Human herpesvirus 1 (HHV-1) Chlamydia pneumoniae Candida albicans Toxoplasma gondii
Human herpesvirus 2 (HHV-2) Helicobacter pylori
Cytomegalovirus (CMV/HHV-3) Borelia burgdorferi
Epstein-Barr virus (EBV, HHV-4) Treponema pallidum
Varicella-zoster virus (VZV, HHV-5) Porphyromonas gingivalis
Human herpesvirus 6 (HHV-6) Fusobacterium nucleatum
Hepatitis C virus (HCV) Prevotella and other periodontal bacteria
Note: The table lists some of the different pathogens that have been associated with Alzheimer’s disease, which range from viruses to protozoa. Porphyromonas gingivalis is 
merely one of the different varieties. Any of these pathogens can be involved in a patient’s Alzheimer’s disease. Hence, treatments that target each specific one would be the best, 
although there is evidence of P. gingivalis involvement, and that other gum disease (periodontal) bacteria are strong.
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The role of gingipain enzymes in neurodegeneration and AD
Gingipains are protease enzymes produced by P. gingivalis that 
are secreted by the bacteria, and can be contained in OMVs.33,36 
Gingipains are correlated with hyperphosphorylated tau and AD 
severity in the brain, and often co-localize with Aβ, NFTs and iron 
deposits.22,36,40 Studies have confirmed its presence in the human 
brain, and one study found this in >90% of post-mortem AD brains 
that contained gingipains.40 It has also been shown that gingipains 
target tau, and truncates it, increasing the self-assembly of tau into 
NFTs.9 P. gingivalis-infected neurons express elevated, abnormal-
ly hyperphosphorylated tau levels and reduced normal tau levels, 
which is most likely the result of the gingipain proteolytic activity 
induced by the effect on tau.40 APP-transgenic mice infected with 
P. gingivalis have been shown to have abundant gingipain levels 
in the brain, which often co-localizes with tau/Aβ, and causes a 
significant increase in Aβ deposition, while the activation of cas-
pase-3, which is involved in apoptosis and tau truncation, results 
in a significant loss of hippocampal neurons.36 These findings are 
consistent with the findings reported by Ishida et al. (2017) and 
Ilievski et al. (2018). However, through infecting mice with P. 
gingivalis, the specific cause of the observed results remains un-
clear,21,23,36 although the presence of gingipains, and its ability to 
effect tau and Aβ makes this the likely culprit.
Gingipain inhibitors have been demonstrated to enter the brain 
of mice, reduce P. gingivalis load, prevent gingipain action on tau 
and gingipain-induced neurodegeneration, and recover degenerat-
ing neurons.36 This makes a strong case for gingipains as a primary 
therapeutic target for P. gingivalis AD.
Lipopolysaccharide and AD
P. gingivalis produces lipid lipopolysaccharide (Pg-LPS), which 
is correlated with neuroinflammation/degeneration.41 Wu et al. 
(2017) and Zhang et al. (2018) demonstrated that Pg-LPS impairs 
spatial learning/memory and significantly increases pro-inflam-
matory cytokine production, which in turn, activates astrocytes/
microglia in mice models.41,42 However, there were inconsisten-
cies between these two studies. One study observed these effects 
in wild-type mice,42 while the other study only observed the same 
effects in cathepsin-B deficient mice, but not in wild-type con-
trols.41 Zhang et al. (2018) did not identify or mention cathepsin 
B-dependency,41 or cited Wu et al. (2017), complicating the in-
terpretation. Despite these, both studies revealed that Pg-LPS can 
cause Alzheimer’s disease pathology. Given that both studies in-
jected mice solely with Pg-LPS, and not the bacteria, it is clear that 
the observed differences are due to Pg-LPS alone.
A similar and more recent study used Pg-LPS to induce the peri-
odontitis mice model that echoed and expanded on these earlier 
findings.43 Pg-LPS-induced neuroinflammation significantly im-
paired spatial learning and memory, as assessed using the Morris 
water maze.43 The levels of pro-inflammatory cytokines, such as 
IL-1β and IL-6, were observed to be significantly elevated due to 
Fig. 2. Overview of the roles of P. gingivalis virulence factors in Alzheimer’s disease. P. gingivalis produces the key neurotoxic secretions: LPS, gingipains 
and PGDHC. Some of the numerous effects were depicted, and all of these mainly cause neuroinflammation via various mechanisms, as well as NFT forma-
tion and Aβ deposition. These contribute to neuronal death, and ultimately, neurodegeneration and AD. It is likely that the effects of each virulence factor 
are more complex, and that there is interplay among a number of other factors, although it must be noted that in the likelihood of AD, P. gingivalis plays a 
part in the disease, and is not the sole initiator/effector of disease progression. AD, Alzheimer’s disease; Aβ, amyloid-β; BBB, blood-brain barrier; GSK3β, gly-
cogen synthase kinase 3β; LPS, lipopolysaccharide; LTD, long-term depression; LTP, long-term potentiation; NFT, neurofibrillary tangle; PGDHC, phosphoglyc-
erol dihydroceramide; P-I, pro-inflammatory; PP2A, protein phosphatase 2A; SASP, senescence-associated secretory phenotype; TLR4, toll-like receptor 4.
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Pg-LPS, and there was a significant increase in activated micro-
glia.43 Overall, these show that Pg-LPS is adept in initiating neu-
roinflammation. Furthermore, Pg-LPS has been shown to increase 
the APP and BACE1 expression, as well as the levels of tau,43 
suggesting that Pg-LPS has a significant influence over key AD 
pathologies. Toll-like receptor-4 (TLR4) recognises LPS, and acti-
vates microglia and other inflammatory processes upon binding,43 
perhaps providing a therapeutic target to prevent Pg-LPS-mediated 
neuroinflammation and Aβ/tau elevation.
Furthermore, Pg-LPS has been reported to induce microglia-
mediated neuroinflammation at the leptomeninges in the blood-
cerebrospinal fluid barrier (BCSFB), which increases pro-inflam-
matory cytokine production.44
Phosphoglycerol dihydroceramides in neurodegeneration and 
AD
The lipid PGDHC is produced by P. gingivalis. Yamada et al. 
(2020) produced compelling evidence suggesting that PGDHC has 
a role in AD.24 In hamster and human neuron cultures exposed 
to P. gingivalis PGDHC (Pg-PGDHC) and P. gingivalis lipopoly-
saccharide (Pg-LPS), it was found that Pg-PGDHC, but not Pg-
LPS, increased the production of APP and Aβ in hamster neurons, 
while tau phosphorylation increased in human neurons. However, 
both Pg-PGDHC and Pg-LPS downregulated sirtuin-1, which is a 
marker for protecting cells from cellular senescence. Furthermore, 
Pg-PGDHC and Pg-LPS increased the senescence-associated se-
cretory phenotype (SASP) in neurons.24 The SASP mark cells for 
apoptosis, and contains pro-inflammatory cytokines and cathepsin 
B.24 There was no explanation for the different effects in hamster 
and human cells. These could be anomalous results, although this 
suggests that the effects of Pg-PGDHC are not universal. Thus, 
further research is required. An earlier study revealed that Pg-
PGDHC can cause apoptosis in human endothelial cells.45 Hence, 
P. gingivalis can use PGDHCs to breach the BBB endothelium and 
enter the brain, although OMVs also provide the mechanism for 
crossing the BBB.46 Further research on the effect of Pg-PGDHC 
on the BBB endothelium is specifically required.
Outer membrane vesicles are potential vehicles for P. gingi-
valis entering into the brain
A point of contention in the literature is to determine whether P. 
gingivalis enters the brain itself in the pathogenesis of AD, or if 
the entry of bacteria into the brain comes at a later stage when P. 
gingivalis secretions, such as Pg-LPS and gingipains, accesses the 
brain using a method, such as OMVs. A number of studies have 
‘detected’ the presence P. gingivalis in the brain, but did not dis-
tinguish between bacterial cells or the secreted virulence factors.22 
This suggests that the presence of P. gingivalis virulence factors 
do not necessarily equate to bacterial presence in the brain, which 
would complicate therapies that target the prevention of bacterial 
access to the brain. However, it is irrefutable that P. gingivalis viru-
lence factors and/or OMVs can reach and enter the brain.22
P. gingivalis produce OMVs that contain a number of bacteria 
virulence factors, including gingipains, LPS and phospholipids.33 
These OMVs are released by P. gingivalis in the oral cavity, al-
lowing these to access the blood, and travel throughout the body, 
including the brain.22,33 OMVs fulfil a number of roles, such as nu-
trient acquisition (often iron),27 communication and host immune 
system evasion, while delivering and spreading virulence factors 
throughout the host and host organs, which are accessed using the 
blood.34 These are mainly produced during bacterial growth, with 
an approximate ratio of 1 bacterium to 2,000 OMVs.34
Nara et al. (2021) reported compelling evidence that suggests 
that OMVs are the key to the ability of P. gingivalis to target ana-
tomically distant organs from the oral cavity, such as the brain.22 
The brain does not appear to be a suitable environment for P. 
gingivalis, that is, the bacteria appears better suited to anaerobic 
polymicrobial films.22 The mechanism and reason(s) by which P. 
gingivalis and/or their virulence factors initially reach the brain to 
influence AD pathologies remain unclear. However, OMVs pro-
vide a solution. That is, there are a number of proposed mecha-
nisms by which OMVs can initially access the brain, and subse-
quently release P. gingivalis virulence factors within the CNS.22,46 
The role of OMVs in the nutrient acquisition of iron can imply 
that P. gingivalis OMVs actively seek the brain as a source of iron, 
given the elevated levels of iron in AD brains.27 A larger number 
of OMVs would likely seek the brain after the initial OMVs have 
already reached the brain, and begun to influence the AD patholo-
gies.22 Nara et al. (2021) suggested that initial P. gingivalis viru-
lence factors that reach the brain in OMVs would localise to areas, 
such as the anterior hypothalamus. The damage caused by the P. 
gingivalis virulence factors and the neuroinflammation caused by 
its presence would begin causing AD pathologies that would, in 
turn, dysregulate lactoferrin release into the oral cavity. Then, this 
would induce the P. gingivalis in the oral cavity to release more 
OMVs that seek iron. As the AD progresses, this would be drawn 
to the brain, given the iron surplus.22,27 Furthermore, the P. gingi-
valis entry into the brain may be made easier through tauopathies, 
which can be observed in AD, and are correlated to BBB dysfunc-
tion.44 Given the ability of P. gingivalis to exacerbate tauopathy in 
the brain,35 the development of tauopathy may worsen the pres-
ence of P. gingivalis and P. gingivalis virulence factors in the brain 
through the induction of BBB dysfunction.
OMVs are capable of increasing BBB permeability, and there 
is evidence that suggests that these can cross the BBB, although 
the latter awaits complete resolution.22,46 Gingipains are contained 
within OMVs, and have been implicated in the process of increas-
ing endothelial permeability.33 OMVs can infect monocytes prior 
to migration to the brain,22 or directly infect cranial nerves and 
spread along these to gain access to the brain.22 Once inside the 
brain, OMVs release P. gingivalis virulence factors, allowing these 
to spread throughout the brain, and cause/contribute neurodegen-
eration and AD.22 Microglia that encounter P. gingivalis virulence 
factors, such as gingipains and LPS, adopt a hypersensitive pheno-
type, which upregulate pro-inflammatory cytokines (such as IL-
1β, IL-6 and TNF-α) and reactive oxygen species (ROS), and con-
tribute to neuroinflammation and degeneration.47 Nonetheless, as 
previously mentioned, P. gingivalis and P. gingivalis secretions are 
adept in evading immune response to an extent that permits persis-
tence within the brain, without preventing neuroinflammation.38,39
OMVs may adopt one of a range of phenotypes.22 Initially, 
these may express high levels of adhesion molecules that assist in 
gaining access into tissues, such as the brain, before adopting an 
‘iron-laden’ phenotype that would cause the greater deposition of 
iron in the brain upon entry.22
GSK3β, Porphyromonas gingivalis and lipopolysaccharide in 
AD
The serine-threonine kinase, glycogen synthase kinase-3β 
(GSK3β), is an isoform of GSK that is widely expressed through-
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out the CNS.13 GSK3β targets a variety of substrates, which in-
clude metabolic proteins, transcription and translation factors, and 
cytoskeletal proteins.16 Furthermore, GSK3β is involved in various 
processes, including synaptic plasticity, memory, neurogenesis, 
and microtubule morphology. All of these become dysregulated 
in AD, and are implicated in inflammation and tau phosphoryla-
tion (Fig. 3).13,14,16 GSK3β activity is negatively correlated with 
tau phosphorylation.13 The exact mechanisms by which GSK3β 
is involved in these processes remain to be fully elucidated, al-
though the role of GSK3β in AD is supported by a wide body of 
evidence.13,14,16 The activity level of GSK3β is regulated by phos-
phorylation at an inhibitory Ser9 site, which is controlled by pro-
tein kinase A and B (PKA and PKB, respectively). The extent of 
the GSK3β phosphorylation/inactivation affects a number of these 
functions.13,14 GSK3β activity increases as age increases, and as 
inhibitory phosphorylation decreases, activating more of the en-
zyme, and contributing to neurodegeneration through a wide vari-
ety of mechanisms.13,16 GSK3β is the key, due its involvement in 
AD, and its susceptibility to being affected by P. gingivalis, par-
ticularly Pg-LPS.13
GSK3β is implicated in a number of AD neurodegenerative 
processes. The enzyme is hyperactive in AD, enabling it to phos-
phorylate many targets, mainly tau, and disrupt key processes that 
contribute to neurodegeneration and AD.14 Furthermore, as a major 
kinase of tau protein, this increases the level of tau phosphorylation, 
contributing to further NFT formation, and ultimately, neurodegen-
eration.13,14 GSK3β is a key contributor to hippocampal LTP/LTD, 
and processes that are vital for memory formation.14 The elevated 
GSK3β activity levels observed in AD would impair LTP and pro-
mote NMDA receptor-mediated LTD, while reducing the pre-syn-
aptic glutamate release.14,16 GSK3β further contributes to AD by 
increasing Aβ formation and accumulation through the modulation 
of amyloidogenic APP processing via BACE1 and γ-secretase.14
Jiang et al. (2021) reported that there are interactions between 
GSK3β and Pg-LPS, which can make numerous contributions to 
AD through microglia-mediated neuroinflammation and tau hy-
perphosphorylation.13 The Pg-LPS itself is capable of causing 
neuroinflammation mediated by IL-1β and TNF-α.13,41,42 Further-
more, Pg-LPS elevates GSK3β activity in neurons, microglia and 
astrocytes.13 The study revealed that Pg-LPS can induce GSK3β 
and TNF-α to interact and modulate the production of one an-
other, raising microglial pro-inflammatory cytokine production, 
and furthering the neuroinflammation.13 This cycle perpetuates as 
Pg-LPS contributes to neuroinflammation, and further raises the 
inflammation while elevating GSK3β activity, leading to increased 
tau hyperphosphorylation, NFT formation and Aβ formation, 
and ultimately leading to neurodegeneration.13 The inhibition of 
GSK3β lowers TNF-α production from the Pg-LPS-activated mi-
croglia, while the inhibition of TNF-α lowers the in vitro activity 
of GSK3β,13 suggesting that these are potential therapeutic targets.
Fig. 3. GSK3β signalling overview. GSK3β is a kinase enzyme regulated by phosphorylation at the Ser9 site. Numerous factors are controlled by phospho-
rylation regulation. The activating signals include LPS in activating TLR4. In this example, the LPS was produced by P. gingivalis. The microglia produced 
TNF-α and IL-17, and both have pro-inflammatory effects, in which one of the effects is the activation of GSK3β. The activation of GSK3β allows the enzyme 
to produce numerous effects, which are mainly pro-inflammatory cytokine modulation and tau phosphorylation. Although correctly regulated, GSK3β 
remains vital for synaptic plasticity and neurogenesis. Conversely, the inhibition of GSK3β can be stimulated by IFNβ and TGFβ binding to their respective 
effects. In AD, GSK3β is hyperactive due to the microglia-produced pro-inflammatory cytokines and P. gingivalis-LPS that stimulate its dephosphorylation. 
AD, Alzheimer’s disease; GSK3β, glycogen synthase kinase 3β; IFNβ, beta-interferon; IFNAR, interferon-alpha/beta receptor; IL-17, interleukin-17; IL-17R, 
interleukin-17 receptor; LPS, lipopolysaccharide; P, phosphate; TGFβ, transforming growth factor-beta; TGFβR, transforming growth factor-beta receptor; 
TLR4, toll-like receptor 4; TNF-α, tumor necrosis factor-alpha; TNFR1, tumor necrosis factor receptor 1.
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Overall mechanism of Porphyromonas gingivalis in AD
It must be initially noted that AD is very complex, and is far from 
being fully understood, particularly when introducing a pathogen, 
such as P. gingivalis, into the proposed mechanism. A very large 
number of variables can effect the onset, development, progression 
and overall timescale of the disease, and the majority of these may 
be unique for each patient. Nara et al. (2021) proposed a compelling 
hypothesis on how P. gingivalis OMVs can be the major driving fac-
tor in P. gingivalis-influenced AD,22 and this counters the proposal 
of Dominy et al. (2019),36 in which gingipains is the key factor.
In summary, P. gingivalis initially infects the oral cavity as a 
small part of a polymicrobial film. In this stage, the bacteria’s iron 
requirement is met through the degradation of salivary lactofer-
rin. Through multiple mechanisms of action, P. gingivalis damages 
the tissue that supports the tooth, in order to allow the OMVs to 
penetrate/bypass the superficial supporting tissue, and reach the 
blood stream. After reaching the blood stream, these OMVs would 
circulate and reach the brain. Using one or more yet to be elu-
cidated mechanism(s), the OMVs will cross the BBB and enter 
the brain. Furthermore, tauopathy has been considered a normal 
characteristic of brain aging, to a certain extent,48 which devel-
ops before the OMVs that reach the brain damages the BBB to 
permit OMVs to cross.44 Nara et al. proposed that OMVs that ac-
cess the brain will localise to areas, such as the basal forebrain, 
hippocampus, and the anterior hypothalamus.22 The content of 
the OMVs released at these sites would induce neuroinflamma-
tion to develop, and lead to numerous effects, such as the induc-
tion of hypersensitive microglia that modulate pro-inflammatory 
response. Gingipains will cleave tau to increase the formation of 
NFTs. In addition, iron deposition would increase due to disrup-
tions in metabolism. At this point, sufficient hypothalamic damage 
may be caused to disrupt the salivary lactoferrin levels, since this 
is upregulated in the brain for its neuroprotective effects, causing 
oral dysbiosis that benefits P. gingivalis, and increasing the OMV 
release with the ‘iron-laden’ phenotype.22 These OMVs will reach 
and access the brain in greater numbers, releasing more Pg-LPS, 
gingipains and Pg-PGDHC, among other secretions, more glob-
ally in the brain, and to areas such as the frontal lobe, temporal 
lobes and neocortex.22 Subsequently, neuroinflammation would 
further increase, since the microglia are activated in larger num-
bers, thereby producing greater quantities of pro-inflammatory 
cytokines, and elevating gingipain, LPS and PGDHC activity and 
influence. The combined effect of these would increase the iron 
deposition, activating more tau kinases such as GSK3β, inhibit-
ing tau phosphatases (PP2A), contributing to NFT formation, and 
ultimately, leading to neurofibrillary degeneration, while modulat-
ing the amyloidogenic processing of Aβ increases the Aβ forma-
tion and deposition throughout the brain. Neurons would die due 
to various mechanisms, including Aβ oligomers/deposits, NFTs, 
aberrant neuroinflammation (microglia, A1 astrocytes), and reac-
tive oxygen species that cause oxidative stress and mitochondrial 
dysfunction. Furthermore, this would cause aggressive cognitive 
decline. Moreover, BBB integrity would fail at some point, exac-
erbating these problems, thereby allowing more P. gingivalis to 
access the brain, and other pathogens and neurotoxic species.
Future directions
All things considered, the contribution of P. gingivalis to AD 
remains irrefutable. It remains unclear exactly how the bacteria 
initially enter the brain, and to what extent the bacteria causes, 
accelerates and/or exacerbates the AD pathology. However, the 
evidence for their contribution cannot be ignored. The bacteria 
are highly accomplished at entering the brain, causing chronic 
neuroinflammation and influencing the AD pathology. A disease 
that is as pervasive as gum disease and has clear links to AD is 
of great concern. The possibilities presented in the present review 
shows that further research on P. gingivalis, each of its secretions, 
its OMVs and potential therapeutic targets must be performed and 
expedited. Given the complexity of AD, specific therapies for each 
patient would be the best approach, and effective P. gingivalis-
based therapies would help a number of patients.
Conclusions
The influence of AD and P. gingivalis on the disease are both 
highly complex, although this presents numerous therapeutic op-
portunities. Evidence for the role of periodontal pathogens such as 
P. gingivalis continues to grow.
One of the most prominent therapeutic targets presented by P. 
gingivalis is the inhibition of gingipains. Dominy et al. (2019) 
reported the promise of this with COR388, a gingipain inhibitor, 
which has been shown to stop P. gingivalis growth and prevent 
gingipain action on tau, while recovering degenerating neurons.36 
COR388 passed the double-blind phase I clinical trial in 2018,49 
and is presently in the double-blind phase II/III clinical trial (to be 
completed by 2023), in order to assess the effect of COR388 on 
cognitive decline and P. gingivalis levels.50 At present, COR388 
appears to be the only P. gingivalis-based therapy in clinical tri-
als (Table 2).15 Further research on therapies based on OMVs, Pg-
LPS and Pg-PGDHC are required, particularly given the apparent 
Table 2.  The range of Alzheimer’s disease therapies presently in phase 3 clinical trials in 201915
Agent Anti-/Non-anti-amyloid Mechanism of action
ANAVEX2-73 Anti-amyloid Anti-tau/-amyloid
Gantenerumab Anti-amyloid Monoclonal antibody
AC-1204 Non-anti-amyloid Induction of ketosis
COR388 Non-anti-amyloid Bacterial protease inhibitor
Escitalopram Non-anti-amyloid Serotonin reuptake inhibitor
Methylphenidate Non-anti-amyloid Dopamine reuptake inhibitor
Note: The above table lists some of the Alzheimer’s disease treatments in phase 3 clinical trials as of 2019. Anti-amyloid denotes those based on the amyloid cascade hypothesis, 
while non-anti-amyloid treatments were based on different hypotheses, such as the Alzheimer’s disease was caused by P. gingivalis. The mechanisms of action of the wide range 
of potential treatments should be explored. AC-1204, tricaprilin; ANAVEX2-73, blarcamesine; COR388, atuzaginstat.
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importance of the initial entry of bacteria into the brain, causing 
neuroinflammation/degeneration.22,45
Given that P. gingivalis-induced neuroinflammation causes 
PP2A inhibition through IL-1β, modulating PP2A and/or prevent-
ing its inhibition may present a promising therapeutic target.10 
Martin et al. (2013) listed two PP2A-targeting drugs, memantine 
and homocysteine, and both of these lower tau phosphorylation, al-
though these require further research in animal models.10 GSK3β, 
which is a major tau kinase modulated by P. gingivalis, is other 
promising therapeutic target, given that it is highly overactive in 
AD. Phosphorylation at its Ser9 residue inactivates the enzyme, 
offering a clear potential therapy that can lower the levels of tau 
phosphorylation. SAR502250 is a selective GSK3 inhibitor that 
has exhibited promising neuroprotective effects in mice models, 
that is, it lowers tau hyperphosphorylation.51
Pg-LPS can be therapeutically targeted via the inhibition of mi-
croglial TLR4. TLR4 recognises Pg-LPS, and the binding of this 
produces a microglia-mediated pro-inflammatory response. In-
hibiting TLR4 can prevent neuroinflammation, and the associated 
damage this causes and exacerbates. Zhou et al. (2020) provided 
a good overview of TLR4 in AD, and listed different therapies for 
targeting TLR4, which have been shown to ameliorate cognitive 
impairment and AD-like pathologies in animal models.52
The testing levels of salivary lactoferrin may provide a biomark-
er of Aβ deposition in the brain and general AD progression.53 De-
creased levels of salivary lactoferrin appears to be unique to AD, 
and contributes to oral dysbiosis, while the levels of lactoferrin are 
elevated in AD.53 It may be considered to test the levels of salivary 
lactoferrin as an early, non-invasive biomarker for AD.
Given that the primary pathogenic effect of P. gingivalis is the 
causation of periodontitis, improvements in oral hygiene in an ear-
ly age would undoubtedly serve to improve dental health, reduce 
the incidence of highly-prevalent periodontitis,30,31 and potentially 
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